Resotyl

Quick links to important sections

Resotyl

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Resotyl

Resotyl is a prescription medication whose active substance is the synthetic compound modafinil, a drug designated as a wakefulness-promoting agent. Its core function is to counter severe, persistent sleepiness by modulating specific activity within the central nervous system. This section defines the medicine’s identity, chemical composition, and pharmacological classification.

Property Description
Active ingredient Modafinil
Form Oral Tablet
Pharmacological class Wakefulness-Promoting Agent (Eugeroic)
Common purpose Relieving excessive daytime sleepiness
Origin Synthetic

Defining the Wakefulness-Promoting Agent

Resotyl's active component, modafinil, belongs to the specialized class of medications known as eugeroics, which are clinically recognized for their ability to promote and sustain alertness. The drug is broadly categorized as a Central Nervous System (CNS) stimulant, although its action profile is chemically and functionally distinct from that of classical amphetamine-like stimulants. Modafinil operates as a sympathomimetic-like agent, primarily used to relieve debilitating excessive daytime sleepiness. A typical use scenario involves managing the profound drowsiness experienced by individuals with hypersomnia.

Composition, Form, and Chemical Structure

The medication is manufactured as a single-ingredient oral tablet for oral administration. The chemical substance, modafinil, is identified as 2-[(diphenylmethyl)sulfinyl]acetamide. It is confirmed to be a racemic compound, meaning the product contains a mixture of both the R-enantiomer and the S-enantiomer of the molecule. This synthetic composition results in a single, solid dosage form. Modafinil exists as this racemic mixture, with the R-enantiomer generally considered the source of its longer-lasting properties.

Understanding Modafinil's Action Profile

The essential function of Resotyl is to promote wakefulness through the targeted modulation of brain signaling. This physiological action involves binding to the dopamine transporter (DAT), which leads to increased levels of dopamine in certain neural pathways. This mechanism, along with effects on other systems like the orexin/hypocretin systems, supports the general management of conditions characterized by hypersomnia, establishing the drug's specialized role in promoting sustained vigilance.

What side effects are possible with Resotyl?

Possible side effects and safety information

The possible adverse effects of Resotyl (modafinil) are officially documented and classified by government regulatory agencies based on the physiological system affected and the established frequency of occurrence. The safety profile is defined by frequency-classified adverse reactions, System-Organ Class (SOC) groupings, and specific notations regarding serious risks.

Frequency and Systemic Adverse Reactions

The most commonly reported adverse reaction, classified as Very Common, is headache. Common adverse reactions, which may affect up to 1 in 10 individuals, frequently involve the nervous system (insomnia, dizziness, anxiety), the gastrointestinal system (nausea, abdominal pain, diarrhea), and the cardiovascular system (tachycardia, palpitations, and increase in blood pressure).

Serious Safety Considerations

The official label highlights the potential for serious adverse reactions. These include severe, potentially life-threatening dermatological reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS. These reactions typically occur within the first five weeks of initiating treatment. Serious psychiatric symptoms are also documented, including the potential for mania, delusions, hallucinations, and suicidal ideation, which may emerge after starting therapy.

Population-Specific Safety Notes and Restrictions

Specific cautions are noted for certain populations. Older adults may require caution due to potential age-related changes in organ function, and those with severe hepatic impairment may require dosage adjustment. The medication is not approved for pediatric use. Additionally, the drug is contraindicated in patients with pre-existing cardiac arrhythmias or moderate to severe hypertension. Use is associated with a risk of developing dependence or misuse, consistent with its status as a wakefulness-promoting agent.

Overdose and Emergency Response

Overdose of Resotyl (modafinil) may present primarily with signs of central nervous system (CNS) excitation and significant cardiovascular changes. Documented CNS manifestations include pronounced agitation, restlessness, disorientation, confusion, anxiety, tremor, and hallucination. Other reported physical manifestations are insomnia, aggressiveness, nervousness, nausea, and diarrhea.

Severe outcomes reported in postmarketing experience include fatal overdoses involving the drug alone or in combination with other substances. Cardiovascular manifestations that necessitate urgent attention are tachycardia (fast heart rate), bradycardia (slow heart rate), hypertension (increased blood pressure), palpitations, and chest pain. The regulatory labeling explicitly states that immediate medical attention is required when severe CNS or cardiac symptoms are observed following suspected over-ingestion.

Management of an overdose focuses on supportive care, as official documentation confirms that no specific antidote exists for the toxic effects of a modafinil overdose. The regulatory procedure mandates that management must include continuous cardiovascular monitoring. Accidental ingestion cases have been reported in children, where the observed symptoms were similar to those experienced by adults.

Therapeutic Uses of Resotyl

What Resotyl Treats: Main Uses and Benefits

Resotyl is commonly used to help address pathological, excessive daytime sleepiness (EDS), which is a symptom related to heightened neurological activity that interferes with daily functioning. The primary goal is to support wakefulness and alertness during scheduled waking hours.

This medication is applied in managing strong feelings of sleepiness when dealing with chronic sleep disorders. The core conditions where Resotyl is relevant for easing symptoms include Narcolepsy, residual sleepiness in patients with Obstructive Sleep Apnea (OSA) who use CPAP, and Shift Work Sleep Disorder (SWSD). This application is relevant in clinical settings that involve periods of heightened symptoms related to hypersomnia.

The core benefit supports the patient by assisting with the management of drowsiness and maintaining functional stability and alertness, helping to ease the overall symptom burden. Resotyl is applied when symptoms create noticeable functional strain, helping to improve day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Excessive Daytime Sleepiness

Resotyl is relevant for conditions characterized by periods of heightened symptoms related to pervasive drowsiness. It is commonly used when supportive symptom management is appropriate to help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Resotyl

The eligibility for using Resotyl (Modafinil) is defined by official regulatory documents, which establish specific criteria for who is allowed, restricted, or prohibited from using the medicine.

Category Eligibility Rule
Approved Population Adults 18 years of age and older with diagnoses of Narcolepsy, Obstructive Sleep Apnea (OSA) adjunct to CPAP, or Shift Work Sleep Disorder (SWSD).
Contraindications Known hypersensitivity to modafinil or armodafinil; history of left ventricular hypertrophy; cardiac valve abnormalities associated with previous CNS stimulant use.
Age Restriction Not recommended for pediatric patients under 18 years; safety and effectiveness are not established in this population.
Organ Function Restriction Use requires caution in patients with severe hepatic (liver) impairment and severe renal (kidney) impairment; a lower dose should be considered in older adults.
Pregnancy and Lactation Not recommended during pregnancy. Use is prohibited while breastfeeding (lactation).
Special Restriction Women of childbearing potential must use effective non-hormonal contraception during treatment and for two months after stopping.

Resotyl's official eligibility profile strictly limits its use to the adult population and prohibits its use in individuals with specific cardiovascular conditions or known allergies. Use in other populations is conditional on monitoring or requires a modified regimen.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Resotyl can alter the effects of numerous other medicinal products through its influence on the cytochrome P450 enzyme system, which is responsible for drug metabolism. It acts as a modest inducer of the CYP3A4/5 enzyme, and also an inhibitor of CYP2C19 and CYP2C9.

Clinically Significant Interactions

Product Category Example Medicines Interaction Result Constraint/Requirement
Hormonal Contraceptives Steroidal Contraceptives Reduced effectiveness. Use alternative/concomitant contraception for 2 months after stopping Resotyl.
Anticoagulants Warfarin Increased risk of effects/toxicity. Requires regular prothrombin time monitoring, especially during the first 2 months or after dose changes.
Anticonvulsants Phenytoin, Carbamazepine Altered plasma concentrations of either drug. Monitoring for signs of toxicity or changes in drug levels is required.
CYP2C19 Substrates Diazepam, Propranolol Decreased clearance and increased concentrations. Dosage reduction may be necessary.

Resotyl's ability to induce CYP3A4/5 activity may decrease the concentration of many co-administered medications that are substrates of this enzyme, including certain statins, calcium channel blockers, and HIV-protease inhibitors. Conversely, its inhibition of CYP2C19 can lead to higher-than-expected levels of drugs metabolized by that enzyme, potentially increasing the risk of associated effects.

Mechanism of Action

How Resotyl Works

The action of Resotyl is defined by its targeted influence on key central nervous system chemical messengers and arousal circuits. The drug’s mechanism results in the modulation of biological pathways that influence arousal and vigilance through distinct, yet coordinated, mechanistic domains.


Modulating Dopamine and Monoamine Reuptake

This domain covers Resotyl’s primary molecular action: the inhibition of the Dopamine Transporter (DAT). By preventing the reabsorption of dopamine back into nerve cells, this mechanism increases the concentration and duration of dopamine signaling in the synapse. This sustained signaling contributes directly to the enhancement of neuronal circuits responsible for motor activation and arousal.


Activating the Orexin Wakefulness System

This domain involves Resotyl's secondary yet crucial action on the orexin/hypocretin system, a critical regulator of the sleep/wake cycle. The drug functions as an agonist at the Orexin Receptor 2 (OX2R), directly stimulating the release of wake-promoting chemicals. This activation results in a fundamental stimulus that affects the physiological state of arousal and vigilance.


Systemic Balance of Excitatory and Inhibitory Signaling

This domain describes the net physiological consequence of the drug's combined actions, which results in a change to the balance of signaling across large neuronal networks. By increasing excitatory input (via dopamine and orexin) and reducing the functional impact of inhibitory output, the net consequence is a systemic change in signaling that promotes a state of arousal and attentional modulation.

Dosage and Administration Information

How to Use Resotyl

Resotyl's (modafinil) administration follows specific protocols regarding the route, schedule, and dosage rules to maintain a standardized regimen. It is supplied as an oral tablet and is taken by mouth only. The tablet must be swallowed whole, and it can be taken with or without food.

Dosing and Schedule

The standard regimen for Narcolepsy and Obstructive Sleep Apnea (OSA) involves taking 200 mg once daily, typically in the morning. For patients managing Shift Work Sleep Disorder (SWSD), the administration is timed to occur approximately one hour prior to the start of the scheduled work shift. The total daily dose may be increased to a maximum of 400 mg per day, taken as a single dose or in two divided doses, for patients who do not achieve an adequate response at the starting dose.

Administration Rules

Condition / Population Administration Rule
Severe Hepatic Impairment The daily dosage should be reduced by half (e.g., to 100 mg).
Older Adults (over 65 years) Therapy should begin at a lower initial dose (e.g., 100 mg daily).
Missed Dose If a dose is missed, do not take a double dose. The dose should be skipped if it is close to bedtime to avoid interfering with sleep.
OSA Treatment Context Used as an adjunct to, and not a replacement for, primary treatments like Continuous Positive Airway Pressure (CPAP).

It is recommended that the patient’s need for continued use should be periodically re-evaluated by a healthcare professional. Use in pediatric patients under 18 years is not recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Resotyl

Evidence for Use in Narcolepsy-Associated Sleepiness

Resotyl was studied in research exploring how symptoms change over time for excessive daytime sleepiness (EDS), a core symptom in individuals with narcolepsy. The primary research comes from short-term, randomized controlled trials (RCTs). These studies primarily compared the measured outcomes in individuals taking the medication against those receiving an inactive placebo over defined time intervals. Research examined outcomes reflecting daily functioning, utilizing objective measures, such as the Maintenance of Wakefulness Test (MWT), and patient-reported outcomes like the Epworth Sleepiness Scale (ESS). Findings describe patterns observed in the studies related to changes in these measures compared to the placebo groups. What remains uncertain is the medication's studied effect on other narcolepsy symptoms, such as cataplexy, where research findings were mixed or inconclusive.

Evidence for Use in Residual Sleepiness in Obstructive Sleep Apnea (OSA)

This evidence was derived from settings where research examined Resotyl as an additional measure for adults with Obstructive Sleep Apnea (OSA) who still experienced persistent sleepiness despite using Continuous Positive Airway Pressure (CPAP) therapy. Studies report how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to measures of sleepiness compared to when patients received a placebo alongside their CPAP therapy. Studies help show what has been observed so far, confirming that Resotyl was studied only as an adjunctive treatment. However, long-term effects are not fully established, as most trials were very short-term, and the interpretation of the evidence supporting this specific indication is not uniform across all major health authorities.

Long-Term Studies and Follow-up Evidence

The primary evidence base consists of core controlled trials that were designed to examine short-term symptom changes, typically lasting only a few weeks to a few months. Research has included open-label extension studies where participants were monitored for longer periods, sometimes up to approximately 40 weeks. However, results apply only to the populations studied in these non-controlled extensions, and long-term effects beyond one year are not fully established.

Key Studies & References

  1. Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis (review detailing MWT/ESS outcomes and long-term concerns)

Frequently Asked Questions (FAQ)

Common questions about Resotyl (FAQ)


Q: How quickly should I expect Resotyl to start working?

According to clinical pharmacology data, the medication typically begins to take effect within 30 to 60 minutes after taking a dose. This information is derived from studies conducted on the drug’s absorption profile.


Q: Are there any specific foods or drinks that interact with Resotyl?

Official documents describe a potential interaction between Resotyl and significant changes in grapefruit consumption, as this could potentially alter the amount of medication in your body. Taking the medication with food is noted to delay its absorption by about one hour.


Q: I'm taking a common cold medicine; is it safe to use Resotyl?

Many common cold and decongestant medicines contain ingredients that act as sympathomimetic agents. Official warnings recommend informing a healthcare professional about all medicines, as the combination can lead to increases in heart rate and blood pressure.


Q: Is Resotyl a controlled substance?

Yes, in the United States, Resotyl (modafinil) is classified as a Schedule IV controlled substance. This classification is given by regulatory authorities due to the potential for dependence or misuse.


Q: Does Resotyl show up on drug tests?

Routine drug screening tests generally do not include testing for modafinil. However, specialized drug tests, such as those sometimes required for competitive athletes, may be able to detect the drug.


Q: How long does Resotyl stay in your system?

Pharmacokinetic data indicates that the drug has a half-life of approximately 15 hours. Metabolites of the drug may be detectable for a longer period depending on the testing method used.


Q: What is the intended 'mechanism of action' for Resotyl in simple terms?

Resotyl is a wakefulness-promoting agent that works by modulating specific chemical messengers in the central nervous system. These chemical messengers, like dopamine and orexin, are responsible for regulating alertness and vigilance. This action helps to sustain a state of wakefulness.


Q: Are there any known interactions between Resotyl and herbal supplements?

Resotyl can influence the activity of the CYP system, which is a key set of liver enzymes involved in drug metabolism. Official warnings state that a healthcare provider should be informed of all supplements and remedies due to this risk of interaction.


Q: Is Resotyl available as a generic medicine?

Yes, the active ingredient in Resotyl, modafinil, is available as a generic medicine.


Q: If I feel better after a few days, can I stop using Resotyl?

Regulatory warnings state that Resotyl should not be discontinued without consulting a healthcare professional. Official guidance notes that the need for continued use requires periodic re-evaluation by a healthcare professional.


Q: Does Resotyl cause weight gain or loss?

Loss of appetite is listed in official adverse reaction data as a common side effect of the medication. The drug is generally not associated with weight gain.


Q: How long do the effects of Resotyl usually last?

The wakefulness-promoting effects of Resotyl can continue for up to 11 hours or more after a single morning dose, according to clinical study data.


Q: Is Resotyl known to cause dry mouth?

Yes, dry mouth is included in the list of potential side effects found in regulatory patient information.


Q: What should I do if Resotyl seems ineffective?

The official regulatory texts indicate that when an insufficient response is observed, the daily dose may be adjusted by a healthcare professional. Continued use also requires periodic re-evaluation.


Q: Can the effectiveness of Resotyl change over time?

Modafinil has a risk of dependence and misuse. Some regulatory data also indicate that the body may increase the rate at which it breaks down the drug over time. Due to these factors, the regulatory requirements stipulate that professional re-evaluation is necessary to assess the ongoing benefit of the medication.


Q: Are there different versions of Resotyl available?

Resotyl (modafinil) is a drug composed of two different forms, or enantiomers (R- and S-forms). The R-enantiomer is also available separately as a distinct, chemically similar wakefulness-promoting medicine.


Q: Do you have to use Resotyl long-term?

Regulatory documents indicate that the long-term effectiveness of Resotyl has not been fully evaluated in clinical trials beyond a few months. For this reason, official guidance notes that the need for continued use requires periodic re-evaluation by a healthcare professional.


Q: Does Resotyl have a black box warning?

The FDA label does not feature a specific Black Box Warning. However, its Warnings and Precautions section contains prominent and serious safety warnings regarding the potential for severe, life-threatening skin rashes and serious psychiatric symptoms.


Q: What happens if Resotyl is taken with alcohol?

Official product information contains a warning against the consumption of alcohol while using Resotyl. There is limited information on the effects of concurrent use, and consuming alcohol may reduce the medication's intended wakefulness-promoting effectiveness.


Q: Can Resotyl interact with over-the-counter pain relievers?

Resotyl can influence liver enzymes (the CYP system) responsible for metabolizing many other medicines, which may include certain pain relievers. Official warnings state that a healthcare provider should be informed of all medications used to assess the potential for interactions.

How should Resotyl be stored and disposed of?

Official Storage and Disposal Requirements

Resotyl's (Modafinil) official storage and disposal instructions are derived from government regulatory documents, focusing on stability, packaging, and safe disposal protocols.

Storage Conditions:

Classification Requirement
Temperature No special storage conditions are required.
Unopened Shelf Life 4 years (as documented in official product information).
In-Use Stability 4 months after opening the container (e.g., HDPE bottle).
Child Safety Store all medication up and away, out of the sight and reach of children.

Handling and Disposal:

The product is packaged in sealed blisters or bottles, which provides necessary protection. Any unused or expired Resotyl must be disposed of in accordance with local regulatory requirements. If a community drug take-back program is unavailable, government guidelines advise removing the tablets from their original container, mixing them with an undesirable substance (such as dirt or used coffee grounds), and placing the mixture in a sealed bag before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Resotyl found in:

A-Z Index: